Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms.
- Author:
Kyung Jin CHUNG
1
;
Benjamin I CHUNG
Author Information
- Publication Type:Review
- Keywords: Lower Urinary Tract Symptoms; Prostatic Hyperplasia; Urinary Bladder, Overactive; Clinical trials as topic
- MeSH: Botulinum Toxins; Clinical Trials as Topic; Hope; Lower Urinary Tract Symptoms; Prevalence; Prostatic Hyperplasia; Rivers; Urinary Bladder, Overactive; Urology
- From:International Neurourology Journal 2017;21(2):97-101
- CountryRepublic of Korea
- Language:English
- Abstract: New drug development is a high-risk venture, but if successful, will bring great revenues to those willing to accept the risk. In the field of urology, in particular for lower urinary tract symptoms (LUTS), the recent successful landing of drugs (e.g., mirabegron, botulinum toxin A, and tadalafil) has resulted in increased interest in new drug development. Benign prostatic hyperplasia and overactive bladder syndrome, representative LUTS diseases, are attractive targets because of their prevalence and market size in the field of urology. Additionally, the awareness about new stream of research is very important not only because of the market size and economic factors, but also because to keep steady attention to these research for the researcher’s. We have reviewed a selection of new drugs currently under development for the treatment of the two aforementioned diseases and hope to offer urologists an overview of the current situation and future directions in the field of urology.
